Prolocor and Slingshot Biosciences Announce Publication in Bioanalysis

Prolocor Inc. and Slingshot Biosciences have announced the publication of their study on the Prolocor pFCG® test in Bioanalysis. This diagnostic test measures the expression of FcγRIIa on platelets, providing a reliable prognostic tool to evaluate thrombotic risk. The use of TruCytes cell mimics, developed by Slingshot Biosciences, enhances the test's precision and accuracy.

Clinical studies show that the Prolocor pFCG® test demonstrates intra and inter-test variations of 2% and 10% respectively, outperforming the FDA's 25% guideline. Dr. David Schneider, Prolocor's Chief Science Officer, emphasized the importance of the partnership with Slingshot Biosciences and the innovation behind the TruCytes cell mimics.

This test aims to help clinicians make informed decisions on antiplatelet therapy, especially for coronary artery disease patients post-stenting. Prolocor and Slingshot Biosciences believe this innovation will significantly enhance patient care.